Metabolic pathways fuelling devil facial tumour diseases

Devil Facial Tumour Diseases (DFTD), threatening Tasmanian devils, consist of two distinct transmissible cancers, DFT1 and DFT2, with differing origins and geographic spread. We investigated the metabolic differences between DFT1 and DFT2, examining cell viability, metabolic outputs, and bulk gene expression. Using both DFT1 and DFT2 cell lines and biopsies, we found that glycolysis, oxidative phosphorylation, glutamate metabolism, and fatty acid synthesis are all essential for the survival of both tumour types. However, DFT2 exhibited higher rates of glycolysis and lactate generation compared to DFT1. This coincided with elevated ATP production, cholesterol biosynthesis, and ROS generation, as well as an increased reliance on fatty acid metabolism. Furthermore, DFT2 is less metabolically adaptable than DFT1, being unable to switch to oxidative phosphorylation as DFT1 can when required. These metabolic changes in DFT2, in conjunction with its higher growth rate, suggest a more aggressive cancer phenotype than DFT1. Our findings highlight distinct metabolic adaptations in DFT2 that may contribute to its competitive advantage.

Authors

Institutions

Publication Details

Journal
FEBS Journal
Published
2026-01-29
DOI
https://doi.org/10.1111/febs.70420
Primary Topic
Veterinary Oncology Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Metabolic pathways fuelling devil facial tumour diseases

Hannah V. Siddle, Mark Ziemann, Antoine Marie Dujon, Matthew McKenzie et al.
FEBS Journal
Veterinary Oncology Research
article

Metabolic pathways fuelling devil facial tumour diseases

Hannah V. Siddle, Mark Ziemann, Antoine Marie Dujon, Matthew McKenzie, Anne‐Lise Gérard, Caitlin Vanbeek, Florence Pirard, Frédéric Thomas, Rodrigo K. Hamede, Aaron G. Schultz
article en

Abstract

Devil Facial Tumour Diseases (DFTD), threatening Tasmanian devils, consist of two distinct transmissible cancers, DFT1 and DFT2, with differing origins and geographic spread. We investigated the metabolic differences between DFT1 and DFT2, examining cell viability, metabolic outputs, and bulk gene expression. Using both DFT1 and DFT2 cell lines and biopsies, we found that glycolysis, oxidative phosphorylation, glutamate metabolism, and fatty acid synthesis are all essential for the survival of both tumour types. However, DFT2 exhibited higher rates of glycolysis and lactate generation compared to DFT1. This coincided with elevated ATP production, cholesterol biosynthesis, and ROS generation, as well as an increased reliance on fatty acid metabolism. Furthermore, DFT2 is less metabolically adaptable than DFT1, being unable to switch to oxidative phosphorylation as DFT1 can when required. These metabolic changes in DFT2, in conjunction with its higher growth rate, suggest a more aggressive cancer phenotype than DFT1. Our findings highlight distinct metabolic adaptations in DFT2 that may contribute to its competitive advantage.

FEBS Journal
Centre National de la Recherche Scientifique (FR), University of Tasmania (AU), Burnet Institute (AU), Deakin University (AU), The University of Queensland (AU), Maladies Infectieuses et Vecteurs: Écologie, Génétique, Évolution et Contrôle (FR), ARC Centre of Excellence for Plant Success in Nature and Agriculture (AU), Institut de Recherche pour le Développement (FR)
Openalex Percentile: Top 75%
Veterinary Oncology Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.